Volume 4, Issue 3, May 2018, Page: 23-30
The Role of the Magnesium Valproate in Therapy for Patients with Treatment-Resistant Depression (TRD): Meat-Analysis Results of Chinese Data
Chen Fengpei, The Graduate School, Zhejiang Chinese Medicine University, Hangzhou, China
Zhu Jianfeng, The Graduate School, Zhejiang Chinese Medicine University, Hangzhou, China
Gao Zhihan, The Graduate School, Zhejiang Chinese Medicine University, Hangzhou, China
Shen Yin, Department of Psychiatry, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Institute, Hangzhou, China
Jin Rui, Department of Pharmacology, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Hangzhou, China
Ren Zhibin, Department of Psychiatry, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Institute, Hangzhou, China
Chen Zhenxin, Department of Psychiatry, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Institute, Hangzhou, China
Ma Yongchun, Department of Psychiatry, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Institute, Hangzhou, China
Jin Weidong, The Graduate School, Zhejiang Chinese Medicine University, Hangzhou, China; Department of Psychiatry, Tongde Hospital Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Institute, Hangzhou, China
Received: Oct. 10, 2018;       Accepted: Nov. 5, 2018;       Published: Dec. 3, 2018
DOI: 10.11648/j.ijpc.20180403.11      View  22      Downloads  16
Abstract
Background: Major depressive disorder is a prevalent and disabling illnessv, approximately 70% of patients do not remit after first-line antidepressant treatment, and about 20% develop to treatment-resistant depression(TRD). Treatment of TRD have been one of clinical problems. Adjunctive valprovate was a most sued ways for treatment of TRD. The magnesium valproate was common drug for both episode and bipolar disorder in China and also was used for TRD. To systematically evaluate the difference in efficacy of magnesium valproate and antidepressants for therapy of treatment-resistant depression(TRD) in China. Methods: Searches were applied to the following electronic databases in china: Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), WANFANG and Chinese Social Sciences Citation Index (VIP) databases. A total of 13 RCTs were included. A meta-analysis was performed of all the literatures germane to estimate the treatment-resistant depression patients treated with magnesium valproate combination with antidepressants and only antidepressants randomized controlled trials (RCTs) from 2010 to 2015. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated and the meta-analysis was conducted with Revman4.2 software. Results: A total of 13 RCTs were included for meta-analysis. The results of meta-analysis demonstrated by effective rate and depressive symptoms change between two groups of combination treatment with magnesium valproate and only antidepressant. The effective rate was higher in magnesium valproate combination with antidepressants group than that in antidepressants group(81/306, 35/298, Z=4.60, P=0.00001). The depressive scale was lower found in magnesium valproate combination with antidepressants group than that in antidepressants group after treatment (Z=16.20, P <0.00001). These results indicated that magnesium valproate combination with antidepressants maybe one better therapeutic way for TRD. Conclusion: The results indicate that magnesium valproate combination with antidepressants was better than antidepressants group in effective rate and improving depressive symptoms during treatment of patients with TRD. So these results may recommend to the patients with TRD though without the differences between groups.
Keywords
Magnesium Valproate, Antidepressants, TRD, Meta-analysis, Chinese Data
To cite this article
Chen Fengpei, Zhu Jianfeng, Gao Zhihan, Shen Yin, Jin Rui, Ren Zhibin, Chen Zhenxin, Ma Yongchun, Jin Weidong, The Role of the Magnesium Valproate in Therapy for Patients with Treatment-Resistant Depression (TRD): Meat-Analysis Results of Chinese Data, International Journal of Pharmacy and Chemistry. Vol. 4, No. 3, 2018, pp. 23-30. doi: 10.11648/j.ijpc.20180403.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014 Mar; 156: 1-7. doi: 10.1016/j.jad.2013.10.043. Epub 2013 Nov 15.
[2]
Carvalho AF, Berk M, Hyphantis TN, McIntyre RS The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom. 2014; 83(2): 70-88. doi: 10.1159/000357500. Epub 2014 Jan 22.
[3]
Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014 Aug 1; 65(8): 977-87. doi: 10.1176/appi.ps.201300059.
[4]
Fife D, Feng Y, Wang MY, Chang CJ, Liu CY, Juang HT, Furnback W, Singh J, Wang B. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017 Jun; 252: 277-283. doi: 10.1016/j.psychres.2017.03.006. Epub 2017 Mar 6.
[5]
Mahlich J Tsukazawa S, Wiegand F. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs Real World Outcomes. 2017 Nov 28. doi: 10.1007/s40801-017-0126-5. [Epub ahead of print].
[6]
Kubitz N1, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013 Oct 18; 8(10): e76882. doi: 10.1371/journal.pone.0076882. eCollection 2013.
[7]
Luan S, Wan H, Zhang L, Zhao H. Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2018 Feb 8; 14: 467-477. doi: 10.2147/NDT.S156619. eCollection 2018.
[8]
Ghabrash MF, Comai S, Tabaka J, Saint-Laurent M, Booij L, Gobbi G. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. World J Biol Psychiatry. 2016; 17(2): 165-70. doi: 10.3109/15622975.2015.1073856. Epub 2015 Oct 7.
[9]
Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Cui X, Calabrese JR, Gao K. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011 Oct; 31(5): 638-42. doi: 10.1097/JCP.0b013e31822bb1d9.
[10]
Barbosa FJ, Hesse B, de Almeida RB, Baretta IP, Boerngen-Lacerda R, Andreatini R. Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol Rep. 2011; 63(1): 64-70.
[11]
Safar MM1, Abdallah DM, Arafa NM, Abdel-Aziz MT. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res. 2010 Jun 2; 1334: 58-64. doi: 10.1016/j.brainres.2010.03.076. Epub 2010 Mar 28.
[12]
Jin WD, Tian Guosheng, Miao Guodong, Liu Tiebang, Fang Yiru, Jia Fujun, Li Jing, Wang Bo, Lu Luxian, Tan Qingrong, Zhang Ning, Li Lingjiang, Xu Yifeng, Hao Wei. Expert consensus of m agnesium valproate sustained release tablets in treatment for bipolar disorder. J Clin Psychol Med. 2012, 22(5): 289-292.
[13]
Li G. Comprison study of magnesium valproate combination with paroxetine in management of treatment-resistant depression(in Chinese). J Clin Psychiatry, 2010, 20(2): 126-127.
[14]
Wang XQ, Pei GX, Zhang YL and Zhou HX. Comparative study between magnesium valproate sustained release tablets with sertraline in the treatment of refractory depression(in Chinese). Medical J Chin People Health. 2010, 22(18): 2321-2324.
[15]
Cui J. The Effects of magnesium valproate sustained release tablets in treatment-resistant depression. J Practical Med Techniques, 2011, 18(6): 648.
[16]
Bian J, Pei SY. The adding effects of magnesium valproate sustained release tablets in treatment-resistant depression(in Chinese). Chin J Health Psychology, 2013, 21(3): 332-333.
[17]
Gao XM, Wang QQ, Hou P and Xu CM. Clincal observation of clinical therapy with duloxetine and magnesium valproate sustained release tablets in depression associated with pain(in Chinese). J Neuro Ment Health, 2013, 13(5): 506-507.
[18]
Xie ZQ, Deng QX and Zuo JF. Paroxetine combined with magnesium valproate sustained release tablets for refractory depression(in Chinese). J International Med Health Guide, 2013, 19(15): 23772378.
[19]
Zhou HX, Wang HY, Ma SJ and Ma XZ. Comparative study of magnesium valproate sustained release tablets with escitalopram in the treatment of refractory depression(in Chinese). J Clin Psychiatry, 2013, 23(4): 220.
[20]
Liu YL, Chen YZ, Zhao XZ and Li CS. Comparative study of magnesium valproate sustained release tablets with escitalopram for treatment-resistant depression(in Chinese). J Clin Psychiatry, 2013, 23(4): 288.
[21]
Yang SX and Han M. The observation of magnesium valproate sustained release tablets with paroxetine for treatment-resistant depression(in Chinese). J Clin Psychiatry, 2014, 24(4): 282.
[22]
Xue XF and Jiang T. Comparative study of escitalopram combing with magnesium valproate sustained release tablets in the treatment of refractory depression(in Chinese). J Chin Rural Health, 2015, 6: 79.
[23]
Li XX. The observation of escitalopram combing with magnesium valproate sustained release tablets for treatment-resistant depression(in Chinese). J Chin Prescription Drug, 2014, 14(4): 69-71.
[24]
Lin T. Comparative study of magnesium valproate sustained release tablets with citalopram for treatment-resistant depression(in Chinese). J Clin Psychosomatic Med, 2015, 12(6): 269.
[25]
Xie ZQ, Deng QX, Deng HJ and Zou YQ. The Clinical study of venlafaxine combing with magnesium valproate sustained release tablets for treatment-resistant depression(in Chinese). J Psychologist. 2012, 6: 106-107.
[26]
Thase ME. New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectr. 2017 Dec; 22(S1): 39-48. doi: 10.1017/S1092852917000876.
[27]
Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017 Jun; 17(6): 593-609. doi: 10.1080/14737175.2017.1283217. Epub 2017 Jan 29.
[28]
Kagawa S, Mihara K, Suzuki T, Nagai G, Nakamura A, Nemoto K, Kondo T. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder Neuropsychobiology. 2017; 75(3): 145-150. doi: 10.1159/000484665. Epub 2018 Jan 12.
[29]
Nugent AC , Carlson PJ , Bain EE , Eckelman W , Herscovitch P , Manji H , Zarate CA , Drevets WC . Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J Psychopharmacol 2013 Oct; 27 (10): 894-902.
[30]
Safar MM, Abdallah DM, Arafa NM, Abdel-Aziz MT. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res. 2010 Jun 2; 1334: 58-64. doi: 10.1016/j. brainres.2010.03.076. Epub 2010 Mar 28.
[31]
Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl). 2006 Apr; 185(2): 255-62. Epub 2006 Feb 22.
Browse journals by subject